A recent study performed by Lead Researcher, Chester Douglass, of Harvard University, unveiled that, investigated bone fluoride levels in individuals with osteosarcoma, (which is a rare, primary malignant bone tumor that is more prevalent in males,) found no serious association between bone fluoride levels and the risk for osteosarcoma was detected in this case-control study.
Logistic regression of the incident cases of osteosarcoma (N=137) and tumor controls (N=51;) adjusting for age and sex, as well as potential confounders of osteosarcoma were used to estimate odds ratios (OR) and 95% confidence intervals (CI.) There was no significant difference in bone fluoride levels between cases and controls. The OR adjusted for age, gender, and a history of broken bones was 1.33 (95% CI: 0.56-3.15.)
In the case-control study, patients were identified by physicians in orthopedic departments from nine different hospitals across the United States between 1993 and 2000.
"The controversy over whether there is an association between fluoride and osteosarcoma has existed since an inconclusive animal study 20 years ago," said IADR Vice President, Helen Whelton. "Numerous human descriptive and case-control studies have attempted to address the controversy, but this study of using actual bone fluoride concentrations as a direct indicator of fluoride exposure represents our best science to date and shows no association between fluoride in bone and osteosarcoma risk."
No comments:
Post a Comment